Investigating the link between unexplained polyneuropathy and wild-type TTR cardiac amyloidosis
Prevalence of Wild-type TTR Cardiac Amyloidosis in Patients With Polyneuropathy of Unknown Cause: a Prospective Monocentric Study (CAP-TTR)
This study is trying to see if people with unexplained nerve problems might also have a heart condition called wild-type TTR cardiac amyloidosis to help diagnose them faster.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 150 (estimated) |
| Ages | 60 Years and up |
| Sex | All |
| Sponsor | Universitair Ziekenhuis Brussel Academic / other |
| Locations | 1 site (Jette, Belgium Capital City) |
| Trial ID | NCT05950867 on ClinicalTrials.gov |
What this trial studies
This study aims to explore the prevalence of wild-type TTR cardiac amyloidosis in patients suffering from chronic axonal length-dependent polyneuropathy (CAP) and/or small-fiber neuropathy (SFN) of unknown cause. Participants will undergo a series of assessments, including symptom evaluation, electrocardiograms, and echocardiography, to determine if these neuropathies are early manifestations of cardiac amyloidosis. The goal is to facilitate faster diagnosis and improve clinical outcomes for patients with this condition. Data from previous medical evaluations will also be analyzed to support the findings.
Who should consider this trial
Good fit: Ideal candidates are patients aged 60 and older with chronic axonal length-dependent polyneuropathy or small-fiber neuropathy without a known cause.
Not a fit: Patients with a known cause of polyneuropathy or those under 60 years old may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to earlier diagnosis and better management of wild-type TTR cardiac amyloidosis in patients with unexplained neuropathy.
How similar studies have performed: While this approach is novel in its specific focus, similar studies have indicated that early identification of cardiac amyloidosis can improve patient outcomes.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with chronic axonal length-dependent polyneuropathy (CAP) and/or small-fiber neuropathy (SFN) without well-defined etiology. * Age: \>= 60 years * Male and female gender * Written informed consent Exclusion Criteria: * Known cause of polyneuropathy * Other types of peripheral neuropathy than chronic axonal length-dependent polyneuropathy (CAP) and/or small-fiber neuropathy (SFN). * Patients younger than 60 years
Where this trial is running
Jette, Belgium Capital City
- UZ Brussel — Jette, Belgium Capital City, Belgium (Recruiting)
Study contacts
- Principal investigator: Veronique Bissay, MD, Phd — UZ Brussel - VUB
- Study coordinator: Véronique Bissay, MD,Phd
- Email: veronique.bissay@uzbrussel.be
- Phone: +32 2 477 68 01
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.